Zometa 4 mg/5 ml (IV Infusion)
4 mg vial: ৳ 10,182.92
Medicine Details
| Category | Details |
|---|---|
| Generic | Zoledronic acid for hypercalcemia |
| Company | Novartis bangladesh ltd |
Title and Categories
- Zometa
- Bisphosphonate preparations
- Medicine
Indications
- Hypercalcaemia of malignancy
- Bone metastases associated with solid tumors
- Osteolytic lesions associated with multiple myeloma
- Corticosteroid-induced osteoporosis
- Increase bone mass in men with osteoporosis
- Osteoporosis in postmenopausal women
- Paget's disease of bone
- Prophylaxis of postmenopausal osteoporosis
Pharmacology
- Belongs to the class of nitrogen-containing bisphosphonates
- Acts primarily on bone
- Inhibitor of osteoclast-mediated bone resorption
- High affinity for mineralized bone
- Possesses anti-tumour activity, anti-angiogenic activity, and anti-pain activity
- Excreted unchanged via the kidney
Dosage
- Maximum recommended dose is 4 mg for hypercalcemia of malignancy
- Recommended dose for multiple myeloma and bone metastases of solid tumors is 4 mg infused every 3-4 weeks
- Patients should also be administered an oral calcium supplement and Vitamin-D daily
Administration
- Zoledronic Acid must be diluted with 100 ml of calcium-free infusion solution
- Infusion duration must not be less than 15 minutes
- Must not be mixed with calcium or other divalent cation-containing infusion solutions
Interaction
- Concomitant use with commonly used anticancer agents, diuretics, antibiotics, and analgesics without interactions
- Caution advised when used with aminoglycosides and thalidomide
- Increased risk of renal dysfunction when used in combination with thalidomide or loop diuretics
Contraindications
- Hypersensitivity to the active substance or any bisphosphonates
- Severe renal impairment
- Pregnancy and lactation
Side Effects
- Headache
- Nausea
- Anemia
- Fatigue
- Constipation
- Osteonecrosis of jaw
- Fever
- Vomiting
- Hypocalcemia
- Myalgia
- Arthralgia
- Hypophosphataemia
Pregnancy & Lactation
- Contraindicated during pregnancy and in breast-feeding women
- Not recommended for use in children and adolescents below 18 years of age
Precautions & Warnings
- Patients must be appropriately hydrated prior to administration
- Serum levels of calcium, phosphate, magnesium, and potassium should be carefully monitored
- Careful renal function monitoring should be considered
Use in Special Populations
- Use not recommended in patients with severe renal impairment
- No dose adjustment is necessary in patients with creatinine clearance >60 ml/min
Overdose Effects
- May cause hypocalcemia, hypophosphatemia, and hypomagnesemia
- Correction by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate
Reconstitution
- Dilute the required amount in 100 mL of NaCl 0.9% or dextrose 5%
Storage Conditions
- Store below 30° C prior to opening
- Protect from moisture and light
- Must be kept out of the reach and sight of children